{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:39:57Z","timestamp":1777642797190,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The management of relapsed aggressive lymphomas remains problematic. Ixabepilone (BMS\u2010247550, epothilone B analog), a potent inhibitor of tubulin disassembly, has promising preclinical and early\u2010phase clinical activity in drug\u2010resistant malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>This multicenter phase 2 clinical trial tested the activity and safety of ixabepilone in relapsed\/refractory aggressive lymphoma patients with either chemosensitive (at least a partial response [PR] to most recent chemotherapy) or chemoresistant (less than PR to most recent chemotherapy) disease at 20 mg\/m<jats:sup>2<\/jats:sup> given intravenously weekly on days 1, 8, and 15 of a 28\u2010day cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Fifty\u2010one enrolled patients with a median age of 66 years received at least 1 dose of ixabepilone. Diffuse large B\u2010cell lymphoma (n = 25; 49%), mantle cell lymphoma (n = 16; 31%), and transformed follicular lymphoma (n = 5; 10%) were the most frequent histologies. Patients were heavily pretreated, with more than one\u2010quarter having received 4 or more prior therapies. The overall response rate was 27% (14 of 51 patients) with 12% (6 patients) experiencing complete responses and 16% (8 patients) with PRs. All responses were in patients with chemosensitive disease. The median time to response was 2 cycles with a median duration of response of 9.7 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Ixabepilone was well\u2010tolerated, with neutropenia, peripheral sensory neuropathy, fatigue, and nausea as the major toxicities. Ixabepilone has modest single\u2010agent activity in patients with recurrent chemosensitive aggressive lymphomas. Cancer 2013. \u00a9 2013 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27917","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T16:08:16Z","timestamp":1357834096000},"page":"1683-1689","source":"Crossref","is-referenced-by-count":8,"title":["A phase 2 study of epothilone B analog BMS\u2010247550 (NSC 710428) in patients with relapsed aggressive non\u2010Hodgkin lymphomas"],"prefix":"10.1002","volume":"119","author":[{"given":"Jane E.","family":"Churpek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Conner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"James L.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0724-8"},{"key":"e_1_2_6_5_2","first-page":"1429","article-title":"BMS\u2010247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee FY","year":"2001","journal-title":"Clin Cancer Res."},{"issue":"1","key":"e_1_2_6_6_2","first-page":"123","article-title":"Paclitaxel\u2010based treatment of lymphoma","volume":"26","author":"Younes A","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.162214"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_9_2","first-page":"583","article-title":"Nonparametric estimation from incomplete observations","volume":"47","author":"Kaplan E","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.7304"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07271.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.1997.15.10.3275","article-title":"Phase II trial of docetaxel in non\u2010Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B","volume":"15","author":"Budman DR","year":"1997","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-46484"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20245"},{"key":"e_1_2_6_17_2","first-page":"502","article-title":"Phase II study of 3\u2010hour infusion of high dose paclitaxel in refractory and relapsed aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte","volume":"85","author":"Casasnovas RO","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.1998.16.2.574","article-title":"Phase II trial of paclitaxel by 24\u2010hour continuous infusion for relapsed non\u2010Hodgkin's lymphomas: Southwest Oncology Group trial 9246","volume":"16","author":"Press OW","year":"1998","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.1995.13.2.381","article-title":"Phase II study of paclitaxel in relapsed non\u2010Hodgkin's lymphomas","volume":"13","author":"Wilson WH","year":"1995","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_20_2","first-page":"489","article-title":"Taxol plus topotecan plus rituximab (TTR) with G\u2010CSF support: an effective salvage program for the treatment of patients with relapsed\/refractory aggressive B\u2010cell non\u2010hodgkin lymphoma (NHL) who failed CHOP\u2010like and platinum\u2010based therapy. Session type: oral session [Abstract]","volume":"102","author":"Younes A","year":"2003","journal-title":"Blood."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011172215216"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1200\/JCO.1995.13.3.583","article-title":"Three\u2010hour paclitaxel infusion in patients with refractory and relapsed non\u2010Hodgkin's lymphoma","volume":"13","author":"Younes A","year":"1995","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400007540"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1182\/blood.V116.21.2806.2806","article-title":"Bendamustine + rituximab as treatment for elderly patients with relapsed or refractory diffuse large B\u2010cell lymphoma [Abstract]","volume":"116","author":"Vacirca J","year":"2010","journal-title":"Blood."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf189"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27917","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:42:03Z","timestamp":1760290923000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1002\/cncr.27917"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27917","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}